January 2008 Oncology News International

Publication
Article

Cover Story

Cost-shifting could sink healthcare system

CMS policy drives fall in ESA use

Anthracyclines in early breast ca: Is the end near?

DEPARTMENTS

Focus on Hematology

Dasatinib promising as induction therapy of Ph+ ALL

Focus on Breast Cancer

Xeloda/Ixempra effective in resistant triple-negative ca

Cancer Care & Economics

Call for congressional hearing on Provenge approval process re-ignites FDA conflict-of-interest controversy

Texas voters listen to Lance

Focus on Lung Cancer

Cetuximab efficacy does not vary with EGFR expression

PET provides clues to improving lung cancer radiotherapy

Focus on Prostate Cancer

Blueberry punch not quite a 'knock out' blow

Recent Videos
Lisa J. States, MD, discussed further steps for improving early detection and screening methods in patients with Li–Fraumeni syndrome.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
9 Experts are featured in this series.
9 Experts are featured in this series.
Additional genetic testing measures and targeted therapies may improve outcomes for patients with diverse molecular subgroups of gastric cancers.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
Related Content
IDE397 Shows Preliminary Efficacy in MTAP+ NSCLC and Urothelial Cancer

IDE397 Shows Preliminary Efficacy in MTAP+ NSCLC and Urothelial Cancer

Russ Conroy
October 28th 2024
Article

Phase 1 expansion data may support potential combination development for IDE397 in NSCLC and urothelial cancer harboring MTAP deletions.

Ginger J. Gardner, MD, FACOG, highlights disease prevention innovations and other ongoing efforts to empower education in the gynecologic cancer field.

Empowering Awareness to Address Rising Gynecological Cancer Incidence

Ginger J. Gardner, MD, FACOG
October 28th 2024
Podcast

Ginger J. Gardner, MD, FACOG, highlights disease prevention innovations and other ongoing efforts to empower education in the gynecologic cancer field.

Mitigating Adverse Effects Following GPRC5DTargeted Therapy in Multiple Myeloma

Mitigating Adverse Effects Following GPRC5DTargeted Therapy in Multiple Myeloma

ONCOLOGY Staff
October 27th 2024
Article

A panel of experts in multiple myeloma discussed strategies for monitoring and mitigating adverse effects associated with GPRC5D-targeting bispecific agents.

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic Diseases

Alexis K. Kuhn, PharmD, BCOP ;Katie Bruce, PharmD, BCPPS;Susie Long, PharmD
October 21st 2024
Podcast

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Evaluating Immunotherapy Options Based on Mutations for NSCLC

Evaluating Immunotherapy Options Based on Mutations for NSCLC

ONCOLOGY Staff
October 26th 2024
Article

Experts discussed the efficacy and durability of immunotherapy responses in patients with NSCLC.

Promising phase 1 data appear to support further evaluation of ZL-1310 as a treatment for patients with extensive-stage small cell lung cancer.

DLL3-Targeted ADC Produces Responses in Previously Treated ES-SCLC

Russ Conroy
October 25th 2024
Article

Promising phase 1 data appear to support further evaluation of ZL-1310 as a treatment for patients with extensive-stage small cell lung cancer.